Abstract:Liver fibrosis is a common wound-healing response to chronic liver injuries, including alcoholic or drug toxicity, persistent viral infection, and genetic factors. Myofibroblastic transdifferentiation (MTD) is the pivotal event during liver fibrogenesis, and research in the past few years has identified key mediators and molecular mechanisms responsible for MTD of hepatic stellate cells (HSCs). HSCs are undifferentiated cells which play an important role in liver regeneration. Recent evidence demonstrates that HSCs derive from mesoderm and at least in part via septum transversum and mesothelium, and HSCs express markers for different cell types which derive from multipotent mesenchymal progenitors. There is a regulatory commonality between differentiation of adipocytes and that of HSC, and the shift from adipogenic to myogenic or neuronal phenotype characterizes HSC MTD. Central of this shift is a loss of expression of the master adipogenic regulator peroxisome proliferator activated receptor γ (PPARγ). Restored expression of PPARγ and/or other adipogenic transcription genes can reverse myofibroblastic HSCs to differentiated cells. Vertebrate Wnt and Drosophila wingless are homologous genes, and their translated proteins have been shown to participate in the regulation of cell proliferation, cell polarity, cell differentiation, and other biological roles. More recently, Wnt signaling is implicated in human fibrosing diseases, such as pulmonary fibrosis, renal fibrosis, and liver fibrosis. Blocking the canonical Wnt signal pathway with the co-receptor antagonist Dickkopf-1 (DKK1) abrogates these epigenetic repressions and restores the gene PPARγ expression and HSC differentiation. The identified morphogen mediated epigenetic regulation of PPARγ and HSC differentiation also serves as novel therapeutic targets for liver fibrosis and liver regeneration. In conclusion, the Wnt signaling promotes liver fibrosis by enhancing HSC activation and survival, and we herein discuss what we currently know and what we expect will come in this field in the next future.

Notch signaling participates in liver fibrosis

Dll4 and Jagged-1 improve liver fibrosis dependent of etiology

Novel Insights on Notch signaling pathways in liver fibrosis

Increased CHCHD2 Expression Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis Via Notch/osteopontin Signaling.

The Annexin A2-Notch Regulatory Loop in Hepatocytes Promotes Liver Fibrosis in NAFLD by Increasing Osteopontin Expression.

The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis

Notch Signaling Contributes to Liver Inflammation by Regulation of Interleukin-22-Producing Cells in Hepatitis B Virus Infection

Notch signaling mediated by TGF-β/Smad pathway in concanavalin A-induced liver fibrosis in rats

Su1677 Blockage of HMGB1 Attenuates Con A-Induced Liver Fibrosis and Regulates the Balance of Treg/TH17 in Vivo

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis

Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis

Expression of Notch family is altered in non‑alcoholic fatty liver disease.

Notch Signaling: Linking Embryonic Lung Development and Asthmatic Airway Remodeling

Notch‐triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through endothelial nitric oxide synthase

Notch signaling regulates pulmonary fibrosis

Notch inhibition promotes fetal liver stem/progenitor cells differentiation into hepatocytes via the inhibition of HNF-1β

Differential effects of targeting Notch receptors in a mouse model of liver cancer

Notch‐Hes1 signaling activation in Caroli disease and polycystic liver disease

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease

Wnt signaling in liver fibrosis: progress, challenges and potential directions